QIAGEN to acquire Parse Biosciences for $225 million in single-cell push
AMSTERDAM – Life sciences company QIAGEN NV said on Monday it has agreed to acquire Parse Biosciences, a provider of single-cell sequencing solutions, for an upfront $225 million in cash, aiming to capture a larger share of the fast-growing market…